MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer

BACKGROUND: Prostate cancer is a common disease in men and at present there is no effective therapy available due to its recurrence despite androgen deprivation therapy. The epidermal growth factor receptor family (EGFR/HER1, HER2/neu and HER3)/PI3K/Akt signaling axis has been implicated in prostate...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Qi, Wenqing, Cooke, Larry S, Stejskal, Amy, Riley, Christopher, Croce, Kimiko Della, Saldanha, Jose W, Bearss, David, Mahadevan, Daruka
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2009
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2685437/
https://ncbi.nlm.nih.gov/pubmed/19432987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-9-142
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items